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There is a signiﬁcant amount of morbidity and mortality follow-
ing myeloablative UCBT, in part secondary to a log less TNC/
CD34 cells/kg infused compared to matched BM or PBSC
(Cairo et al, Blood, 1997). RI conditioning followed by BM or
matched PBSC may potentially reduce the incidence of TRM and
the late effects associated with myeloablative regimens without
increasing the risk of graft failure or relapse (Satwani/Cairo,
BBMT, 2005). Since UCB has a log less cells, it remains to be
determined whether RI conditioning will be as successful when
combined with UCBT. We currently report the results of RI-
UCBT in 21 pediatric pts, median age 7.5 years (0.33-20 yrs). HLA
match: 4/6 -13, 5/6-5, 6/6-3. Malignant diseases n14, Hodgkin’s
disease n5 (CR2-2, SD -1 and PD-2), NHL n2 (ALCL-PR1
and DLBCL-SD), CML (CP-1), AML n3 (CR1-2and CR2-1),
MDS n3 and non-malignant diseases n7, HLH-2, WAS-1,
B-Thal-1, SAA -1, SCID’s-2. RI conditioning consisted of ﬂudara-
bine (150-180mg/m2)with either busulfan (8mg/kg)ATG (n16)
or cyclophosphamideATGetoposide (n5). GHVD prophy-
laxis consisted of FK-506 and MMF (Osunkwo/Cairo, BBMT,
2004). The median TNC/ kg was 3.58107(0.92-22.61) and the
median CD34 cell dose/kg was 2.54105(0.34- 9.57). The me-
dian time for neutrophil and platelet engraftment was 17.5 days
(1-47) and 52 days (6-170), respectively. There were 6 primary
graft failures (1 CML, 1 b-Thal, 2 HLH, 1 MDS, and 1 AML), 4/6
who were regrafted with myeloablative conditioning followed by a
UCBT achieved100% engraftment. In the remainder 14 evaluable
patients the donor chimerism at 30 and 180 days was 74 20% and
90 10%, respectively. The probability of developing grade II-IV
aGVHD and cGVHD was 28.6% and 16.7%, respectively. Inci-
dence of TRM was 14%. The 2yr OS in all patients was 59.8%
(CL95: 37.9-81.6). The 2yr OS for patients with average risk
malignancy was 77.8% (CL95: 50.6-100) and poor risk malignancy
was 20.2% (CL95: 0-55.1). These preliminary results indicate that
despite a log less TNC/CD34 cells/kg infused compared to
matched BM or PBSC, RI-UCBT may result in rapid hematopoi-
etic reconstitution while decreasing TRM compared to myeloab-
lative UCBT and be associated with high donor chimerism. Pa-
tients with some diseases such as CML, b-Thal, and HLH may
require increased intensity of conditioning. Further follow-up is
required to evaluate long-term effects in pediatric patients follow-
ing RI-UCBT.
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We have reported the feasibility of reduced-intensity cord blood
transplantation (RICBT) for elderly patients with hematological
malignancies at the last Tandem meeting (Abstract#18). Despite of
its efﬁcacy, treatment-related mortality (TRM) at day 100 post-
transplant was considerably high (50%). Our preliminary data
suggested that tacrolimus (TAC) as GVHD prophylaxis reduced
TRM. Therefore, we conducted a retrospective analysis of 35
consecutive patients55 years who underwent RICBT with single
CB unit at our institute using TAC as GVHD prophylaxis from
Jan. 2004 to Apr. 2006. Diagnoses were AML/MDS (21), CML (4),
ALL (6), and ML (4), 11 of them were categorized as standard risk
(those who were in CR, CP, and untreated MDS) and 24 of them
were as high risk diseases (other than standard). Median total
nucleated cell and CD34 cell numbers were 2.25 10E7 /kg
(range, 1.82-3.6) and 0.78 10E7 /kg (range, 0.11-1.9), respec-
tively. Thirty-two patients (91%) were conditioned with 125 mg/
sqm of ﬂudarabine, 80 mg/sqm of melphalan, and 4 Gy of TBI, and
the other 3 were with slight modiﬁcation. TAC was started at day
-1 of transplant at 0.03 mg/kg for 24 hr. Thirty-three of them were
treated with TAC alone, and 2 were with TAC and mycophenolate
mofetile. Eight patients died before day 28. Among the remaining
27 patients, 24 (88.9%) of them achieved neutrophil engraftment
at a median 19 days (range, 12-33). Fifteen out of 25 (60%) and 9
out of 17 (53%) evaluable patients experienced acute GVHD
(grade II-IV: 12, III-IV: 8) and chronic GVHD (limited: 5, exten-
sive: 4), respectively. Twelve patients (37%) died before day 100
post-transplant. At the median 420 days post-transplant (range,
54-773), 18 survived, with 16 being disease-free. Overall (OS) and
progression-free survival at 1 year post-transplant were 54.6% and
41.3%, respectively. Remarkably, OS at 1 year post-transplant for
those with standard risk diseases was 91%, whereas it was 38% for
those with high risk. Among 17 deaths observed, 6 were from
disease progression and the other 11 were from non-relapse causes.
Multivariate analyses revealed that age older than 60, poor ECOG
performance status (2) before transplant, higher disease risk were
associated with an increased risk for mortality. To conclude,
RICBT with TAC is a feasible approach for elderly patient, espe-
cially for those with standard risk diseases. Longer follow-up is
necessary to further evaluate the curability of this approach.
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Clinical trials using unrelated donors are accepted choices world-
wide for patients in need of transplant but lacking HLA-matched
related donors. To study the outcome we reviewed our experience
with 28 Thai pediatric patients (22 male; 6 female) given hemato-
poietic stem cell transplantations from unrelated donors (UD-
HSCT) selected using DNA high-resolution typing of both HLA
class I and II loci, from May 2001 to September 2006. Median age
and weight were 7 years 7 months (1 y 3 m-16 y 9 m), and 24.5 kg
(7.8-68.8), respectively. Twenty patient/donor pairs (71.43%) were
fully matched; eight (28.57%) were 5/6 matched. Patients had
either non-malignant (n23) or malignant (n5) diseases. Among
non-malignant group there were beta-thalassemia major (n16),
adrenoleukodystrophy (n3), severe aplastic anemia (n2), Wis-
kott-Aldrich syndrome (n1), and Griscelli syndrome (n1); while
there were acute lymphoblastic leukemia (n2), chronic myeloid
leukemia (n1), juvenile chronic myelomonocytic leukemia (n1),
and relapsed Hodgkin disease (n1) in malignant group. Besides
umbilical cord blood transplant (CBT) recipients (n3) for whom
graft-versus-host disease (GvHD) prophylaxis with mainstay cyclo-
sporine was used, GvHD prophylaxis for bone marrow (BMT) and
peripheral blood stem cell transplant (PBSCT) composed of cy-
closporine plus short-term methotrexate in ﬁrst 12 recipients;
tacrolimus plus short-term methotrexate in last 13. Median num-
bers of infused CD34 cells were 5.15106/kg (1.24-33.6) in
BMT (n17), 6.8106/kg (3.91-17.17) in PBSCT (n8), and
3105/kg (2.26-25) in CBT (n3). The probability of hematopoi-
etic recovery at day 30 was 85.71%. Of the engrafted patients
(n25) the cumulative probability of acute and chronic GvHD
were 32 and 16%, respectively. Ten patients died of transplant-
related complications. The probability of transplant-related mor-
tality (TRM) at 30 days, 100 days, 1 year, and 2 years were 10.71,
28.57, 28.57, and 35.71%, respectively. Median follow-up time for
surviving patients was 1 year 6 months (2 m-5 y 4 m). Overall (OS)
and disease-free survival (DFS) rates were 64.29 and 57.14%,
respectively. Of the beta-thalassemia patients group (n16) the OS
and DFS rates were superior; 81.25 and 75%, respectively. UD-
HSCT with donor selection based on high-resolution HLA typing
is associated with low incidence of graft failure and GvHD. This
observed outcome is favorable and comparable to that of children
transplanted from HLA-identical siblings.
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